Johnson & Johnson has agreed to acquire Alios BioPharma Inc. for $1.75 billion in cash. Alios is in the process of developing a drug for respiratory viral infection, which has no approved treatment as of yet. In the deal Alios also gives J&J access to a portfolio of drug targeting other viral infections. AL-8176 is the experimental drug Alios is working on. It treats infants with respiratory syncytial virus and is currently in the mid stage trails.